Kwaliz Plus Tablet contains a combination of Clonazepam (0.5 mg) and Escitalopram Oxalate (10 mg), formulated to manage anxiety disorders and depression. Clonazepam, a benzodiazepine, exerts anxiolytic, anticonvulsant, and muscle-relaxant effects by enhancing the activity of gamma-aminobutyric acid (GABA) in the central nervous system, thereby producing a calming effect. Escitalopram Oxalate, a selective serotonin reuptake inhibitor (SSRI), increases serotonin levels in the brain by inhibiting its reuptake into presynaptic neurons, which helps improve mood and reduce anxiety symptoms. The combined action of these agents provides a synergistic effect, offering rapid relief from acute anxiety and sustained improvement in depressive symptoms. Kwaliz Plus is indicated for the treatment of generalized anxiety disorder, panic disorder, and major depressive disorder, especially in patients requiring both immediate anxiolytic action and long-term antidepressant therapy. It should be used under strict medical supervision due to potential side effects such as drowsiness, dizziness, gastrointestinal disturbances, and the risk of dependence associated with benzodiazepines. Dose adjustments may be necessary in hepatic or renal impairment. Patients should avoid alcohol and operating heavy machinery while on this medication. Regular follow-up is recommended to monitor therapeutic response and adverse effects.